Report : A-Z NHS England items in Formulary 18/01/2021 13:45:00

[Back]

Section Status NHS England Name 08.01.05 Formulary Alectinib  08.01.05 Formulary Arsenic Trioxide Trisenox® 10.01.03 Restricted Use Avelumab Bavencio ® 08.02.04 Formulary Axicabtagene ciloleucel  YESCARTA® 03.14 Formulary Benralizumab  08.01.05 Formulary Brigatinib Alunbrig® 04.08.01 Formulary Cannabidiol Epidyolex® 08.01.05 Formulary Cemiplimab  08.01.05 Formulary Ceritinib  Zykadia® 08.01.03 Formulary Cytarabine–daunorubicin liposomal Vyxeos® 08.01.05 Formulary Dabrafenib with Trametinib  08.01.05 Formulary Dacomitinib  08.01.05 Formulary Daratumumab Darzalex ® 08.02.03 Formulary Dinutuximab  08.01.05 Formulary Durvalumab  08.02.03 Formulary Gemtuzumab Mylotarg® 05.03.03.02 Formulary Glecaprevir–pibrentasvir Maviret® 08.01.05 Formulary Ibrutinib Imbruvica® 08.02.03 Formulary Inotuzumab ozogamicin Besponsa ® 08.01.05 Restricted Use Ixazomib  03.04.03 Formulary Lanadelumab Takhzyro® 08.01.05 Formulary Larotrectinib Vitrakvi® 08.01.05 Formulary Lenvatinib Kisplyx ® 05.03.02.02 Formulary Letermovir  08.01.05 Formulary Lorlatinib Lorviqua® 08.03.04.03 Formulary Lutetium (177Lu) oxodotreotide  03.14 Formulary Mepolizumab (Nucala®)  08.01.05 Formulary Midostaurin  Rydapt® 08.01.05 Formulary Neratinib Nerlynx® 08.01.05 Formulary Niraparib  08.01.05 Formulary Niraparib  10.02 Formulary Nusinersen  08.02.03 Formulary Ocrelizumab  08.02.04 Formulary Peginterferon beta-1a Plegridy ® 03.11 Restricted Use Pirfenidone Esbriet® 08.01.05 Formulary Rucaparib Rubraca® 05.03.03.02 Formulary Sofosbuvir-velpatasvir-voxilaprevir  09.05.02.02 Formulary Sucroferric oxyhydroxide Velphoro® 08.01.05 Formulary Tisagenlecleucel Kymriah® 08.01.05 Formulary Tivozanib Fotivda®

Birmingham, Sandwell, Solihull and environs APC Formulary